Document:

EXHIBIT 10.1

 

AMENDMENT TO THE REGISTRATION RIGHTS AGREEMENT

 

This Amendment (this “Amendment”), dated as of January 21, 2018, is made by Idera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Amendment (collectively, the “Investors”).

 

WHEREAS, the Company and the Investors are parties to that certain Registration Rights Agreement, dated as of February 9, 2015 (as amended, modified or supplemented from time to time, the “Registration Rights Agreement”);

 

WHEREAS, Section 3.1 of the Registration Rights Agreement provides that the Registration Rights Agreement may be amended by written instrument executed by the Company and the Investors;

 

WHEREAS, the Company and the Investors desire to amend the Registration Rights Agreement pursuant to the terms hereto in order to reflect the parties’ original intent; and

 

WHEREAS, capitalized terms used and not otherwise defined herein have the meanings set forth in the Registration Rights Agreement.

 

NOW, THEREFORE, in consideration of the covenants and agreements contained herein and in the Registration Rights Agreement and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:

 

A.                                    Amendment to the Registration rights Agreement.  Section 3.5 of the Registration Rights Agreement is hereby amended to add the following sentence immediately before the last sentence thereof:

 

“The Company shall not consummate any recapitalization, merger, consolidation, reorganization or other similar transaction whereby stockholders of the Company receive (either directly, through an exchange, via dividend from the Company or otherwise) equity (the “Other Equity”) in any other entity (the “Other Entity”) with respect to Registrable Securities hereunder, unless prior to the consummation thereof, the Other Entity assumes, by written instrument, the obligations under this Agreement with respect to such Other Equity as if such Other Equity were Registrable Securities hereunder.”

 

B.                                    Miscellaneous. This Amendment and the Registration Rights Agreement, together, contain the complete agreement among the parties and supersede any prior understandings, agreements, letters of intent, or representations by or among such parties, written or oral, to the extent they relate to the subject matter hereof. Except as specifically amended hereby, the Registration Rights Agreement, as amended hereby, shall remain in full force and effect.  The terms and provisions of Section 3 of the Registration Rights Agreement (as amended hereby) are incorporated herein by reference as if set forth herein in their entirety and shall apply mutatis mutandis to this Amendment.

 

*                                         *                                         *                                         *                                         *

 

 

IN WITNESS HEREOF, the parties have executed or caused this Amendment to be executed as of the date first written above.

 

 

	
 
    	
IDERA   PHARMACEUTICALS, INC.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ Vincent J. Milano
    
	
 
    	
 
    	
Name: Vincent J. Milano
    
	
 
    	
 
    	
Title: President and   Chief Executive Office
    

 

[Signature Page to Amendment to Registration Rights Agreement]

 

 

IN WITNESS HEREOF, the parties have executed or caused this Amendment to be executed as of the date first written above.

 

 

	
 
    	
667, L.P.
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
BAKER BROS ADVISORS LP,   management company and investment adviser to 667, L.P., pursuant to authority   granted to it by Baker Biotech Capital, L.P., general partner to 667, L.P.,   and not as the general partner
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/ Scott L. Lessing
    
	
 
    	
 
    	
 
    	
Name: Scott L. Lessing
    
	
 
    	
 
    	
 
    	
Title: President
    
	
 
    	
 
    
	
 
    	
BAKER BROTHERS LIFE SCIENCES,   L.P.
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
BAKER BROS ADVISORS LP,   management company and investment adviser to Baker Brothers Life Sciences, L.P.,   pursuant to authority granted to it by Baker Brothers Life Sciences Capital,   L.P., general partner to Baker Brothers Life Sciences, L.P., and not as the   general partner
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/ Scott L. Lessing
    
	
 
    	
 
    	
 
    	
Name: Scott L. Lessing
    
	
 
    	
 
    	
 
    	
Title: President
    
	
 
    	
 
    
	
 
    	
14159, L.P.
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
BAKER BROS ADVISORS LP,   management company and investment adviser to 14159, L.P., pursuant to   authority granted to it by 14159 Capital, L.P., general partner to 14159,   L.P., and not as the general partner
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/ Scott L. Lessing
    
	
 
    	
 
    	
 
    	
Name: Scott L. Lessing
    
	
 
    	
 
    	
 
    	
Title: President
    
					

 

[Signature Page to Amendment to Registration Rights Agreement]

 

 

SCHEDULE A

 

THE INVESTORS

 

14159, L.P.

 

667, L.P.

 

BAKER BROTHERS LIFE SCIENCES, L.P.Exhibit 4.1

 

	                    NUMBER 

         

        U-                     

        
	 	UNITS                      

  

	SEE REVERSE FOR 

        CERTAIN DEFINITIONS 
	MTECH
    ACQUISITION CORP.	 

  

CUSIP 55378W
206

 

UNITS
CONSISTING OF ONE SHARE OF CLASS A COMMON STOCK, AND ONE WARRANT 

EACH
WARRANT TO PURCHASE ONE SHARE OF CLASS A COMMON STOCK

  

	THIS CERTIFIES THAT	 	 

  

	is the owner of	 	Units.

  

Each Unit
(“Unit”) consists of one (1) share of Class A common stock, par value $0.0001 per share (“Common
Stock”), of MTech Acquisition Corp., a Delaware corporation (the “Company”), and one warrant
(the “Warrant(s)”). Each Warrant entitles the holder to purchase one (1) share of Common Stock for $11.50
per share (subject to adjustment). Each Warrant will become exercisable on the later of (i) 30 days after the Company’s
completion of a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business
combination (“Business Combination”) and (ii) twelve (12) months from the closing of the Company’s
initial public offering (“IPO”), and will expire unless exercised before 5:00 p.m., New York City Time,
on the fifth anniversary of the completion of an initial Business Combination, or earlier upon redemption (the “Expiration
Date”). The Common Stock and Warrants comprising the Units represented by this certificate are not transferable
separately prior to the 90th day after the date of the prospectus relating to the Company’s IPO, subject to earlier separation
in the discretion of EarlyBirdCapital, Inc., provided that the Company has filed with the Securities and Exchange Commission a
Current Report on Form 8-K which includes an audited balance sheet reflecting the Company’s receipt of the gross proceeds
of the IPO and issued a press release announcing when separate trading will begin. The terms of the Warrants are governed by a
Warrant Agreement, dated as of                     ,
2018, between the Company and Continental, as Warrant Agent, and are subject to the terms and provisions contained therein, all
of which terms and provisions the holder of this certificate consents to by acceptance hereof. Copies of the Warrant Agreement
are on file at the office of the Warrant Agent at 1 State Street 30th Floor, New York, NY 10004-1561, and are available to any
Warrant holder on written request and without cost.

  

This
certificate is not valid unless countersigned by the Transfer Agent and Registrar of the Company.

 

Witness
the facsimile seal of the Company and the facsimile signatures of its duly authorized officers.

 

	By	 	 	 
	 	Chairman
    of the Board	 	Chief
    Executive Officer

  

     

     

    

  

MTech
Acquisition Corp.

  

The
Company will furnish without charge to each stockholder who so requests, a statement of the powers, designations, preferences
and relative, participating, optional or other special rights of each class of stock or series thereof of the Company and the
qualifications, limitations, or restrictions of such preferences and/or rights.

  

The
following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were
written out in full according to applicable laws or regulations:

  

	TEN COM	-	as tenants
    in common	UNIF
    GIFT MIN ACT-	 	 Custodian 	 	 
	TEN ENT	-	as
    tenants by the entireties  	 	 	(Cust)	 	(Minor)	 
	JT TEN	-	as joint tenants with right of survivorship	under Uniform Gifts to Minors	 	 
	 	 	and
    not as tenants in common	Act	 	 	 	 	 
	 	 	 	 	               (State)	 	 	 	 

 

Additional
abbreviations may also be used though not in the above list. 

	 	 	 	 	 
	For
    value received,                      hereby
    sell, assign and transfer unto

 

 

	PLEASE INSERT SOCIAL SECURITY OR OTHER 

        IDENTIFYING
        NUMBER OF ASSIGNEE 
	 
	 	 
	 

         

         

         
	 

  

	(PLEASE
    PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING ZIP CODE, OF ASSIGNEE)
	 

 

	 	 	 Units

represented
by the within Certificate, and do hereby irrevocably constitute and appoint

  

	 	 	 Attorney to transfer

the said
Units on the books of the within named Company will full power of substitution in the premises.

  

Dated____________

 

	 	 
	 	Notice:	The
    signature to this assignment must correspond with the name as written upon the face of the certificate in every particular,
    without alteration or enlargement or any change whatever.

  

Signature(s)
Guaranteed:   

	 	 	 	 	 
	THE
    SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS
    AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15).	 	 

  

The holder(s)
of this certificate shall be entitled to receive a pro-rata portion of the funds from the trust account with respect to the common
stock underlying this certificate only in the event that (i) the Corporation is forced to liquidate because it does not consummate
an initial business combination within the period of time set forth in the Corporation’s Amended and Restated Certificate
of Incorporation, as the same may be amended from time to time (the “Charter”) or (ii) if the holder seeks to convert
his shares upon consummation of, or sell his shares in a tender offer in connection with, an initial business combination or in
connection with certain amendments to the Charter. In no other circumstances shall the holder(s) have any right or interest of
any kind in or to the trust account.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}]]